TPCN2 and neoplasm: While the temporary inhibition of TPC2 using, e.g., the tetrandrine-derived TPC2 inhibitor, SG094, has demonstrated anti-tumor effects in vivo, with reduced toxicity and improved potency compared to the parent molecule tetrandrine, the long-term consequences of TPC2 inhibition remain speculative [26].